Can One Evening of Alcohol Change Intestinal-Barrier Blood Markers for 48 Hours? A 22-Volunteer Study

Short answer: In one prospective experiment involving 22 healthy adults, an evening of alcohol consumption was followed by a transient rise in serum intestinal fatty-acid binding protein (I-FABP/FABP-I) at six hours and sustained elevations in serum soluble CD14 (sCD14) at six, 24, and 48 hours. The authors considered these patterns consistent with possible intestinal-barrier disturbance and increased endotoxin-related immune signaling. They did not directly measure circulating endotoxin as the decisive endpoint, diagnose intestinal injury in any individual, test driving performance, or demonstrate a particular person’s alcohol-caused medical outcome. The result is evidence about group biomarker responses, not a forensic test of culpability, impairment, or causation.

The primary source is Sturm and colleagues’ controlled human exposure study, Acute alcohol consumption increases systemic endotoxin bioactivity for days in healthy volunteers—with reduced intestinal barrier loss in female, published online in 2021 and in the 2022 volume of the European Journal of Trauma and Emergency Surgery. The complete original research is available through DOI: 10.1007/s00068-021-01666-4.

What was actually tested?

The investigators enrolled 22 clinically screened volunteers, 12 women and 10 men, aged 18–50. They excluded volunteers with several chronic or inflammatory conditions or medication exposures that could complicate interpretation. The participants ate a standardized lunch before receiving whiskey mixed with cola in equal servings every 20 minutes over four hours. Each person’s dose was calculated with a modified Widmark equation to target an alcohol concentration of about 1 per mille at the end of drinking. This was a planned exposure target, not a measured value at the time of the initial calculation.

Sampling began before drinking and continued at two, four, and six hours after the beginning of consumption, followed by serum collection at 24 and 48 hours. Urine was collected before dosing and in pooled two-hour intervals through six hours. The design is important: the 24- and 48-hour biomarker measurements are after the start of drinking, not after an independently established time of complete elimination.

The experiment was prospective and used each participant’s predose sample as a reference. It did not randomly allocate an ethanol group against a simultaneously observed beverage-placebo group. Therefore, time effects, the standardized meal, the cola mixer, and other unmeasured factors cannot be eliminated by comparison with an independent sober control arm. That design limits causal conclusions even when repeated measurements differ statistically from baseline.

Which specimens and analytes were directly measured?

Whole blood was drawn and processed into serum, using serum-gel tubes and centrifugation. The authors describe alcohol concentrations determined by a clinical laboratory in serum. Their paper refers to those results as BAC, but a concentration obtained from separated serum is not automatically a directly analyzed forensic venous whole-blood ethanol concentration. The full analytical method, calibration and blood-to-serum conversion needed to treat it as a case-specific whole-blood value were not validated by this experiment.

The three main biological markers were assayed by enzyme-linked immunosorbent assay (ELISA). I-FABP (also written FABP-I or FABP2) is a protein associated with intestinal epithelial cells and can increase in blood with epithelial stress or injury. Syndecan-1 is a proteoglycan associated with epithelial and endothelial biology. Soluble CD14 interacts with lipopolysaccharide (LPS)-related innate immune signaling and can be an indirect marker of endotoxin bioactivity. An sCD14 concentration is not a direct quantitative assay of endotoxin molecules in plasma, nor a microorganism culture or a measurement of a person’s clinical sepsis state.

Because the samples differ, the relevant question must be specified. A serum ethanol measurement answers a different question from a serum sCD14 measurement, a urine I-FABP concentration, a direct LPS test, or a behavioral impairment task. Combining these endpoints under the single phrase “positive alcohol blood test” would confuse chemical exposure with inferred tissue physiology.

What alcohol concentrations did the researchers observe?

Although the planned terminal concentration was 1‰, the authors’ actual reported mean serum-alcohol results rose over time. At two hours, the cohort mean was 0.46 ± 0.02‰; at four hours it was 1.11 ± 0.05‰; and at six hours it was 0.83 ± 0.06‰. Their plot and text report no detectable alcohol at 24 and 48 hours. These are the original authors’ group mean ± standard error measures expressed with their per-mille label, not individual results or forensic whole-blood assays.

There was no statistically significant male–female difference in the reported serum-alcohol concentration profiles. That limited finding provides some context for comparing biomarker patterns, but it does not show equal individualized dose, identical pharmacokinetics, or the absence of sex-related confounding. Participants received calculated, body-dependent quantities of beverage.

What did the serum intestinal FABP measurements show?

The study reported a nonmonotonic response. The mean serum I-FABP concentration began at 441.30 ± 44.15 pg/mL before drinking, then decreased to 355.90 ± 35.44 pg/mL at two hours and 338.50 ± 38.40 pg/mL at four hours. Both early values were reported significantly below baseline. At six hours, the mean rose to 552.20 ± 56.83 pg/mL, which was significantly above baseline (the authors used p < 0.05 for these contrasts). The direction changed over the drinking-and-follow-up period.

This time pattern matters in interpretation. A higher serum I-FABP result at six hours is not accurately described as “I-FABP rose continuously while alcohol was consumed.” Nor can the initial decline be erased simply because a later rise occurred. The early drop could reflect complex redistribution, feeding-related effects or intestinal function rather than a straightforward ethanol dose-to-injury curve. The original authors discussed prior food intake as a plausible contributor.

Mean I-FABP remained numerically higher at 24 and 48 hours, but those later differences were not statistically significant in the reported analyses. Loss of participants at later blood draws further restricts confidence in late comparisons. The study therefore does not establish a sustained statistically significant I-FABP elevation for two entire days, even though sCD14 behaved differently.

Did soluble CD14 remain elevated after ethanol became undetectable?

Yes, in the cohort’s measured serum sCD14. Baseline mean sCD14 was 3,432.00 ± 258.40 ng/mL. It rose to 4,388.00 ± 398.50 ng/mL at six hours, 5,363.00 ± 312.50 ng/mL at 24 hours, and 5,300.00 ± 324.20 ng/mL at 48 hours. The authors reported each of those three postdrinking time points as significantly higher than predose baseline (p < 0.05). The later values were recorded when the study no longer detected serum ethanol at its reported test intervals.

This is precisely why the terms ethanol detection and biological response should not be conflated. A measured analyte can return below an assay’s detection threshold while some associated physiological markers remain altered. But the magnitude or persistence of one group marker cannot be converted into a subject-specific estimate of prior BAC, drinking time, amount consumed, intoxication or injury.

Soluble CD14 can derive from several biological processes, including immune-cell shedding and hepatic production. It can also participate in neutralizing LPS, not simply amplify inflammation. Thus, higher sCD14 is not synonymous with directly measured higher circulating LPS, and this study did not prove bacterial translocation or clinical infection in its participants.

What are the numerical results, separated by specimen and inference?

For the highlighted comparisons, “higher” or “lower” denotes the paper’s reported significance at p < 0.05, not an independently reconstructed paired confidence interval. The table is an original explanatory rearrangement of the source’s observations rather than a new dataset or an individual prediction rule.

Did syndecan-1 also increase, and what changed in urine?

The cohort’s overall serum syndecan-1 concentration did not show a significant change across sampling times compared with baseline. Before alcohol, the reported serum mean was 2.15 ± 0.56 ng/mL. The absence of an overall significant change is important because it prevents treating all three biomarkers as if they rose in lockstep.

Urinary syndecan-1 was 3.39 ± 0.24 ng/mL before alcohol and fell to 2.33 ± 0.21 ng/mL in the urine collected during the interval ending at four hours, a reported significant reduction. It later returned toward the baseline range. Urinary I-FABP similarly declined in the pooled collection ending at four hours, from 16.24 ± 3.90 to 5.06 ± 3.40 pg/mL, then approached initial values by six hours.

The urine values are concentrations in pooled collection intervals, not instantaneous urine measurements precisely matched to one venous draw. Hydration and renal handling may influence urinary concentrations independently of the amount of marker released by enterocytes. These results do not prove that intestinal permeability itself was directly measured or quantify the passage of a defined endotoxin mass into blood.

What did the comparison between women and men establish?

Women generally had lower syndecan-1 concentrations than men in serum and urine during the observation period. Serum I-FABP was lower among women at two hours. Baseline sCD14 was higher among women, while later sex-specific sCD14 levels did not show significant differences in the investigators’ results. Group alcohol concentrations were not significantly different by sex.

Those observations are not sufficient to conclude that all women sustain less intestinal damage from alcohol, or that an individual woman’s immune response can be predicted from sex alone. Female and male groups numbered only 12 and 10. The study did not randomize participants to sex, demonstrate a validated sex-by-time causal interaction for each clinical outcome, or measure an actual post-trauma infectious complication. A difference in marker level at a particular time is not necessarily a difference in the causal response to ethanol.

Does the FABP-to-sCD14 correlation prove endotoxin moved through the gut?

The source describes a significant Spearman association between serum I-FABP at two hours and serum sCD14 at 24 hours: r = 0.8182, p < 0.05. The figure legend specifies n = 12 for this correlation, rather than all 22 recruited volunteers. The correlation is an association between two measured host proteins at different times, not a measurement of movement by LPS or bacteria between organs.

Even a high rank correlation does not determine the source of sCD14, establish the molecular pathway, or rule out shared physiological drivers. Its subgroup denominator and repeated exploratory analyses limit external generalization. A case-specific inference that a person’s alcohol intake caused measured bacterial leakage, trauma infection or organ failure would require clinical and laboratory evidence not supplied by this experiment.

Why is this study relevant to traumatic-injury and toxicology interpretation?

Clinical trauma investigations often encounter a patient’s measured alcohol concentration together with inflammatory, metabolic and organ-injury markers. They also may investigate whether an infection or inflammatory complication developed later. This study supports a biologically plausible hypothesis that alcohol exposure can be followed by measurable systemic responses after ethanol is no longer detected. It is not a validation study for attributing complications to alcohol in an injured patient.

All 22 enrolled subjects were healthy volunteers. No one was assigned a traumatic hemorrhage, bowel injury, surgery, septic shock, resuscitation protocol, hypothermia, or anticoagulant treatment as part of the study. The investigators observed biomarkers, not infection diagnoses, mortality, intensive-care admissions, driving errors, workplace accidents or forensic disability. The paper’s observations cannot supply the missing causal comparison between an injured patient with alcohol exposure and that same patient without exposure.

A rigorous review must connect each conclusion to its specific measurement. See the site’s published guides to specimen collection and handling, pharmacokinetic interpretation and direct forensic whole-blood ethanol measurement by gas chromatography. Those methods answer distinct evidentiary questions and should not be merged into an unspecified “blood test.”

What is the evidence ladder from exposure to causation?

Which methodological uncertainties matter most?

The comparison is mainly within persons, not against a contemporaneous no-alcohol group. The standardized meal, mixer and time under observation may contribute to temporal biomarker changes. Because everyone drank alcohol, one cannot directly subtract a time-matched sober trend from an exposed trend. The protocol may demonstrate temporal association more convincingly than a uniquely isolated ethanol effect.

The sample is small and later follow-up incomplete. The 12-woman and 10-man groups were not powered as large definitive effect-modification cohorts. The authors acknowledge missed 24- and 48-hour collections. A group mean with a reported SEM is not an interval within which every person’s result must fall; it also does not describe analytic assay uncertainty without a separate validation.

There are several outcomes and time points. FABP, syndecan-1 and CD14 were assessed in different matrices over repeated intervals, including subgroups. The authors used Kruskal–Wallis/Dunn comparisons and Spearman correlations with a nominal p < 0.05 criterion. The multiplicity of exploratory endpoints and the single smaller-subset correlation should be considered rather than counting a few significant markers as independent proof of a pathway.

Markers are not interchangeable with diagnoses. I-FABP is not the same as measured permeability in a functional permeability test. Syndecan-1 changes can reflect several tissue processes. Soluble CD14 can arise from more than one source and is not itself LPS. Any statement that “endotoxin was demonstrated to translocate from the gut” would go beyond the directly measured analytes in this paper.

Alcohol exposure was not individualized for legal reconstruction. A modified Widmark formula defined the experimental dose. Subsequent values came from the authors’ reported clinical serum testing. Neither a dosing formula nor a cohort curve justifies reconstructing event-time venous whole-blood BAC, a legal impairment threshold or specific decision-making in a person whose samples and circumstances differ.

Frequently asked questions

Does this paper prove alcohol damages the intestine for 48 hours?

No. It reports a statistically significant six-hour serum I-FABP elevation and serum sCD14 elevations at six, 24 and 48 hours. The later I-FABP increases were not significant, and direct tissue injury or permeability was not confirmed by an independent diagnostic gold standard.

Was endotoxin directly measured in blood?

No quantitative circulating-LPS result is established as the study’s measured endpoint. The authors interpreted soluble CD14 as a surrogate for endotoxin-related bioactivity. That supports a narrower physiological inference, not proof of an endotoxin molecule’s concentration or origin.

Were the reported BAC measurements forensic venous whole-blood results?

No. The authors determined alcohol concentration using clinical serum samples and reported the values with a BAC label. Serum ethanol and properly validated forensic whole-blood ethanol are different analytical matrices and must not be treated as synonymous.

Could a person have no detectable alcohol but still show altered biomarkers?

In this study the group had no detectable reported serum ethanol at 24 and 48 hours while group sCD14 remained elevated. That is evidence of a marker time course, not a universal person’s detection window or a test for earlier drinking.

Does a difference between women and men prove one sex is protected?

No. Some marker levels differed across the 12 women and 10 men, but small subgroups, baseline differences and the absence of directly measured clinical damage prevent an individualized protection rule.

Can elevated sCD14 establish that alcohol caused sepsis after an accident?

No. The participants were healthy and did not experience the relevant trauma or sepsis outcomes as experimental endpoints. A patient-specific infection analysis must examine clinical course, microbiology, exposures, alternative causes and properly contextualized tests.

Can these markers establish whether a driver was impaired?

No. The paper did not test driving, standardized sobriety performance, decision-making, reaction-time impairment or a validated classifier. A marker association cannot replace contemporaneous case and functional evidence.

How should the study be cited in forensic analysis?

Sturm R, Haag F, Janicova A, Xu B, Vollrath JT, Bundkirchen K, Dunay IR, Neunaber C, Marzi I, Relja B. Acute alcohol consumption increases systemic endotoxin bioactivity for days in healthy volunteers—with reduced intestinal barrier loss in female. European Journal of Trauma and Emergency Surgery. 2022;48:1569–1577. https://doi.org/10.1007/s00068-021-01666-4.

The scientifically defensible bottom line is narrow but important: in a small controlled-drinking time-course study, some serum biomarkers changed well after alcohol ingestion, including persistent sCD14 elevation at 48 hours. The measurements support exploration of gut-barrier and innate-immune mechanisms. They do not establish directly measured bacterial translocation, individual impairment, clinical infection or cause in a particular legal case.